ロード中...
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
The treatment of patients with myelodysplastic syndromes (MDSs) has hinged primarily on supportive care (ie, blood transfusions, colony stimulating agents, iron chelation, etc.) and the US Food and Drug Administration-approved agents, including 5-azacytidine, deoxyazacytidine, and lenalidomide. For...
保存先:
| 出版年: | Hematology Am Soc Hematol Educ Program |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142467/ https://ncbi.nlm.nih.gov/pubmed/27913518 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|